Search Videos by Topic or Participant
Browse by Series:

Frontline TKI Selection in Metastatic RCC

Insights From: Prof. Bernard Escudier, MD, Institute Gustave Roussy; Susanne Osanto, MD, PhD, Leiden University Medical Center
Published: Tuesday, Jan 05, 2016


Most patients with metastatic renal cell carcinoma (RCC) have good a performance status. In these patients, a tyrosine kinase inhibitor, such as sunitinib or pazopanib, is the usual first-line option, notes Benard Escudier, MD. Interferon with bevacizumab, however, is still used in some patients, such as those who have lung metastases, he adds.

For Susanne Osanto, MD, the patient’s comorbidities play a role in the decision between sunitinib and pazopanib. Prior to the data reported from COMPARZ, Osanto tended to prefer sunitinib in patients with liver metastases and a large tumor burden. However, the drugs appear to be equally effective for most patients, she notes, adding that pazopanib is the drug of choice in elderly patients who are very frail, since it is easier to administer.

The PISCES trial was a patient preference study looking at pazopanib and sunitinib in RCC. The results showed that patients and physicians preferred pazopanib over sunitinib. Comorbidities are not really a factor for Escudier, who says he uses pazopanib more often than he uses sunitinib. However, he adds, there are not enough data to support the use of pazopanib in patients with non-clear cell histology RCC.
Slider Left
Slider Right


Most patients with metastatic renal cell carcinoma (RCC) have good a performance status. In these patients, a tyrosine kinase inhibitor, such as sunitinib or pazopanib, is the usual first-line option, notes Benard Escudier, MD. Interferon with bevacizumab, however, is still used in some patients, such as those who have lung metastases, he adds.

For Susanne Osanto, MD, the patient’s comorbidities play a role in the decision between sunitinib and pazopanib. Prior to the data reported from COMPARZ, Osanto tended to prefer sunitinib in patients with liver metastases and a large tumor burden. However, the drugs appear to be equally effective for most patients, she notes, adding that pazopanib is the drug of choice in elderly patients who are very frail, since it is easier to administer.

The PISCES trial was a patient preference study looking at pazopanib and sunitinib in RCC. The results showed that patients and physicians preferred pazopanib over sunitinib. Comorbidities are not really a factor for Escudier, who says he uses pazopanib more often than he uses sunitinib. However, he adds, there are not enough data to support the use of pazopanib in patients with non-clear cell histology RCC.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x